Lyra Therapeutics Estimates That It Will Incur Charges Of About $3.9M-$4.1M In Connection With The Workforce Reduction; Expects That The Majority Of Charges Related To Workforce Reduction Will Be Incurred In Q2 Of 2024
Portfolio Pulse from Benzinga Newsdesk
Lyra Therapeutics has announced that it expects to incur charges of approximately $3.9 million to $4.1 million due to a workforce reduction. The majority of these charges are anticipated to be incurred in the second quarter of 2024, according to an SEC filing.
June 07, 2024 | 8:22 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Lyra Therapeutics is set to incur charges between $3.9 million and $4.1 million due to a workforce reduction, with the majority of these charges expected in Q2 2024.
The announcement of workforce reduction and associated charges is likely to have a negative short-term impact on LYRA's stock price as it indicates potential operational challenges and additional costs.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100